Drug Profile
Botulinum toxin A - Galderma
Alternative Names: QM1114; QM1114-DP; RelabotulinumtoxinALatest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Galderma
- Developer Galderma; Q-Med
- Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antipruritics; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Recombinant proteins; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Facial wrinkles; Glabellar lines
Most Recent Events
- 17 Jan 2024 Efficacy and adverse events data from the phase III READY-3 trial in Glabellar-lines and Facial-wrinkles released by Galderma
- 30 Nov 2023 Efficacy and adverse events data from a phase IIIb (43QM2106) trial in Facial wrinkles (Glabellar frown lines) released by Galderma
- 30 Nov 2023 Efficacy and adverse events data from a phase IIIb (43QM2107) trial in Facial wrinkles released by Galderma